Biotechnology
SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory inCopenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and...
2022-03-08 15:31
1975
Turn Bio adds veteran executives with decades of international business development, intellectual property expertise
Hires will help to expand Turn's commercial reach, protect its unique ERA Platform technology MOUNTAIN VIEW, Calif., March 7, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure now-untreatable, chronic, age-related conditions, today ann...
2022-03-07 20:00
3571
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs
TAIPEI, March 7, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract dev...
2022-03-07 09:00
2731
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technolo...
2022-03-07 09:00
3137
CNN's Vital Signs explores the future of medicine
HONG KONG, March 3, 2022 /PRNewswire/ -- From personalized vaccines to
lab-grown organs and AI-powered medical devices, the future of medicine is
happening right now in labs across the world. This month on CNN's 'Vital Signs'
2022-03-03 10:13
3875
Four new leaders join Cargill's executive team, aligned to company's innovation strategy and customer priorities
MINNEAPOLIS, March 2, 2022 /PRNewswire/ -- Four new leaders are joining Cargill's executive team. They were selected for their expertise aligned to evolving customer and employee needs and their potential to drive the company's innovation and sustainability strategies around the world. "The food...
2022-03-02 14:16
3567
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...
2022-03-02 08:47
4134
Cambrex Expands Biopharmaceutical Services Business
EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...
2022-03-01 22:00
3729
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketin...
2022-03-01 17:30
3906
Lifebit and Boehringer Ingelheim announce partnership to capture transformational value of health data
* Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable data, analytics, and infrastructure platform * This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precisi...
2022-03-01 14:00
3853
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-03-01 08:48
3956
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Added 18,985 New Subscribers in 3Q22 Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million) Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Mil...
2022-03-01 05:16
4088
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...
2022-03-01 05:01
4050
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...
2022-02-28 22:15
4232
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
2022-02-27 18:30
6505
Jean-Luc Herbeaux to become Hovione CEO
LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that
the Board of Directors and the shareholders have approved the appointment of
Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April
2022.
2022-02-25 22:00
3586
Fosun Foundation's First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong
HONG KONG, Feb. 25, 2022 /PRNewswire/ -- In an effort to support Hong Kong's fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation ofHK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks toHong Kong. ...
2022-02-25 12:33
5469
Prenetics Partners with ACON Bio to Launch Flowflex(TM) COVID-19 Home Antigen Test in Hong Kong - the Most Accurate Test in the Market
Most Accurate Based on 2 Independent Validation Studies Across 53 Antigen Test Kits*
* To ensure accessibility, the United States FDA EUA authorized test will be
one of the most affordable tests in the market atHKD60
* Flowflex™ will be available on projectscreen.co
2022-02-25 09:53
5694
Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
NEW YORK and HONG KONG, Feb. 25, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in a Phase I clinical trial evaluating ISM001-055, the first anti-fibroti...
2022-02-25 00:00
5356
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is w...
2022-02-23 21:27
3240
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 298 media titles]
2026-06-04 23:55
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
8232
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7623
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
7180
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6740